Qing Chen and Hua Xun participated in the Taiwan Biotechnology Exhibition three times, and signed a contract with Gene Online!

 

2022Year7Month28Day-On July 31,Asia is extremely influential [Taiwan Biotechnology Exhibition]],Grand exhibition in Taipei Nangang Exhibition Hall Hall 2, the industry is optimisticChinaTaiwan's biotechnology industry is booming, with domestic and foreign biotechnology giants invited to participate in the exhibition.15 participating countries, more than 50 listed enterprises, 550 large index factories, using 1500 booths,DominateThe two-storey exhibition hall of Nangang Exhibition Hall fully shows the complete pulse and achievements of the biotechnology industry from research and development to application. Show BiotechMedicineTechnology at all stages of the field, significant cross-strait and internationalIndustryTrends, as well as the investment prospects of biotech stocks and other strictly selected information.

 

 

This isTaiwanQingchenLaw FirmwithNanjingHua Xun caseIntellectual Property Consultants LimitedThird year exhibition.

 

In addition to participating in the exhibition this year,7Month29DayAfternoonQingchen Law Firm and Gene Online, co-hosted.The theme is“How does a company succeed? Valuation and authorization are not known."Seminar and cooperation signing activities between the two sides,Invite experts from all walks of life to targetbiotechnology medicinePatent Layout and M & A StrategyproceedCommunication.

 

The seminar was a combination of online and offline, with more than 100 offline participants and more than 40,000 online participants.This meeting invited the valuation of the biotechnology industry, authorized professionals, investors, as well as experts with practical and successful experience of the company representatives, to sharepatent layout strategy,valuation of biotechnology companies, examples of authorizations,In-depth discussion of how biotechnology pharmaceutical companies can use the help of the capital market to accelerate the success of technology maturity towards marketization.

 

Qing Chen Legal AffairsBywithGene OnlineSuccessA cooperation signing ceremony was held to help accelerate the marketization of biotechnology companies in Asia and the United States and seize new industrial opportunities.

 

Taiwan Pharmaceutical Development AssociationLi FangquanThe chairman said in his speech that patent protection is quite rigorous in the field of medicine and is a good mechanism to promote industrial competition. Patent layout depends more on long-term and complete planning.

 

 

Taipei Bio-Industry AssociationZhang LiyanThe chairman said that in recent years, China's Taiwan industry has moved towards the international market, and the overall professional layout has a key influence on entering the global market competition.

 

Warwick International Technology PartnerLin HanfeiSharing, the past.The main industries of Taiwan's economy in 30 years include science and technology semiconductor and bicycle industry. If the pharmaceutical industry compares these two industries, it actively grasps the opportunities of upstream and downstream integration, market development, regulations and IP layout, and strives for international capital, and the output value is expected to increase by 2-3 times.

 

 

Chairman of Taiwan Precision Medical Industry AssociationLee Jong-heeHe said that the biotechnology and pharmaceutical industry is not only a technology and manufacturing link, but also financial investment, legal affairs and intellectual and financial rights are not only indispensable, but also the biggest obstacle to the development of biotechnology in Asia. In the future, the combination of industrial cooperation mechanism and professional knowledge will help to move towards internationalization.

 

 

Executive Partner of Qingchen Law FirmHou QingchenLawyers to "Comparison of Chinese and American Medicine Patent Linking System" In his speech, Mr. Hou mentioned that "patents are a game for big countries" and that the value of patents in mainland China will only become higher and higher in the future. In addition to sharing cases of patent invalidation litigation in China, lawyer Hou also carefully introduced two major aspects of patent invalidation attacks: internal and external defects of patents.

 

 

Taishan InvestmentWang JiahuiAssociate of the biotechnology fund, sharing "from the perspective of investors AI technology, applied in the field of medical knowledge management "issues. Associate Wang introduced many successful cases of the combination of AI and biotechnology, including the use of AI to record long-term cell activities and molecular structure technology. Venture capital companies have seen investment opportunities in such emerging technologies and have also enabled pharmaceutical or biotechnology companies to explore the feasibility of more intellectual and financial management.

 

The highlight of this event is the celebration of Chen& Gene OnlineCooperation signing! Huang Funan, CEO of Gene Online, said that Qingchen Law Firm is deeply involved in patents and medicine, and knows a lot about the industrial development in mainland China. He hopes to serve more companies through cooperation and develop into the global market in combination with the professional development of both parties.

Lawyer Hou Qingchen also mentioned that the key to winning is that the biotechnology technology must be mature, coupled with the two major tools of patent foundation and information exposure, which will help the biotechnology industry in Taiwan, please climb another tall building.

 

Vice President of Cambridge CapitalZheng Youren, from the capital level and we share 《Capital cross-border new strategy, another wave of mergers and acquisitions wind", Mr. Zheng's analysis of global healthcare over the past two decades tells us about the macro trends driving healthcare spending in the Asia-Pacific market and the China market, and the growth of the Asia-Pacific pharmaceutical market and the China market. At present, Chinese pharmaceuticals are shifting from fast followers to innovators. Although the market is currently in a downturn, major pharmaceuticals/Biotech's business performance remains strong, showing the industry's resilient business fundamentals, which can only survive through restructuring, prioritization and streamlining.

 

 

At the end of the activity, the specially invited host, Deputy General Manager of Yi Wei Biopharmacy/General manager of Jiangsu HuahanLi YueningAnd a number of guests launched a wonderful panel discussion。

 In view of the differences in the patent linking system between Taiwan and mainland China, it is not only related to the differences in litigation systems in various regions, the different duration of litigation, but also related to the maturity of the judicial system.

 Facing the "capital winter" in the field of biotechnology investment, experts share from The VC perspective will be more prudent in assessing the controllability of RD risk and the company's potential for international development when selecting investment targets. There are also companies that do not choose traditional VCs, but instead use convertible corporate bonds to raise capital.

 Finally, discuss SPAC and traditional IPO listing path difference, 2020-2021 first half of the biotechnology industry SPAC case peak, but with the IPO market stabilization, and biotechnology IPO and other enterprises compared to the lower threshold, no profit requirements, the future of biotechnology enterprises to choose different listing paths of the tendency is worth further observation.

 

The forum was successfully concluded. Qingchen and Hua Xun thanked everyone who supported and participated online and offline!

Looking forward to seeing you next time!